Good Works II Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in Houston, Texas.
IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Good Works II Acquisition Corp. (0001850487) (Issuer)
4 - Good Works II Acquisition Corp. (0001850487) (Issuer)
4 - Good Works II Acquisition Corp. (0001850487) (Issuer)
4 - Good Works II Acquisition Corp. (0001850487) (Issuer)
4 - Good Works II Acquisition Corp. (0001850487) (Issuer)
4 - Good Works II Acquisition Corp. (0001850487) (Issuer)
Fastest customizable press release news feed in the world
Good Works II Acquisition Corp. (NASDAQ:GWII) ("Good Works II"), a publicly traded special purpose acquisition company ("SPAC"), and Direct Biologics, LLC ("Direct Biologics"), a late-stage biotechnology company, today announced the signing of a definitive agreement that, upon the satisfaction of all closing conditions, will result in Direct Biologics becoming a publicly traded company. Upon transaction close, which is expected to occur in the first half of 2023, the combined company will be named Direct Biologics, Inc. and shares of its common stock are expected to trade on the Nasdaq Capital Market. Cary Grossman, Chief Executive Officer of Good Works II, commented, "We formed Good Works
Direct Biologics leverages a proprietary extracellular vesicle platform technology designed to harness the power of bone marrow-derived mesenchymal stem cells to develop cell-free therapeutics Product candidate, ExoFlo™, is in a Phase 3 clinical trial for treating moderate-to-severe acute respiratory distress syndrome in hospitalized adults with severe-to-critical COVID-19 Proposed transaction values Direct Biologics at an enterprise value of $675 million Good Works II Acquisition Corp. (NASDAQ:GWII) ("Good Works II"), a publicly traded special purpose acquisition company ("SPAC"), and Direct Biologics, LLC ("Direct Biologics"), a late-stage biotechnology company, today announced the sig
15-12G - Good Works II Acquisition Corp. (0001850487) (Filer)
25-NSE - Good Works II Acquisition Corp. (0001850487) (Subject)
8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
425 - Good Works II Acquisition Corp. (0001850487) (Subject)
8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
10-Q - Good Works II Acquisition Corp. (0001850487) (Filer)
425 - Good Works II Acquisition Corp. (0001850487) (Subject)
8-K - Good Works II Acquisition Corp. (0001850487) (Filer)
This live feed shows all institutional transactions in real time.
SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G/A - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)
SC 13G - Good Works II Acquisition Corp. (0001850487) (Subject)